September 13th, 2010 by David Kroll, Ph.D. in Better Health Network, Health Policy, News, Opinion, Research
No Comments »
I’m only a monthly contributor here, but between being a Science Based Medicine (SBM) reader and having my own blogs, I often grow weary of the blind criticism that researchers and drug companies couldn’t care less about traditional folk medicines as drug products. My laboratory spends every single day working on natural product extracts in the search for compounds that may have selective effectiveness against cancer. So this is a bit of a sore spot for me.
Two [recent] papers from Cancer Prevention Research on the potential anticancer effects of a diabetes drug (see Nathan Seppa’s story here) remind me to tell the story of a Middle Ages European herbal medicine used to treat polyuria that gave rise to one of the most widely prescribed drugs in the world, metformin (Glucophage in the U.S.). Metformin, known chemically as a biguanide, dimethylguanide to be precise, traces its roots to the plant Galega officinalis. Known as goat’s rue, French lilac, or professor weed, this plant was shown to be a rich source of guanidine and a less toxic compound later called galegin or galegine (isoamyline guanidine). Read more »
*This blog post was originally published at Science-Based Medicine*
September 5th, 2010 by DrWes in Better Health Network, Health Policy, Opinion, True Stories
No Comments »
I received the following e-mail from a patient (paraphrased):
Dear Dr. Fisher,
Thank you for trying to switch me from lisinopril to generic losartan (Cozaar) to help me with the irritating cough that has been nagging me since I was placed on lisinopril. I did not pick up my prescription, though. At nearly $200 for a three-month supply, I’ve decided to live with the cough, since the same amount of lisinopril costs me about $12.
-Ms. Patient
Interesting how the generic drug market for some drugs only marginally discounts prices. Since the companies that make generics did not have to absorb research and development costs, how do they justify the exorbitant prices? Simple: The middlemen still have to get theirs.
-WesMusings of a cardiologist and cardiac electrophysiologist.
*This blog post was originally published at Dr. Wes*
September 2nd, 2010 by RyanDuBosar in Better Health Network, Health Policy, News, Research
No Comments »
Patients are pill-splitting more to trim back healthcare costs, according to a poll by Consumer Reports. In the past year, 39 percent took some action to cut costs.
The poll of more than 1,100 people found that 45 percent of people take at least one prescription drug and average four. But 27 percent said they didn’t always comply with a prescription, and 38 percent of those younger than 65 without drug coverage didn’t fill prescriptions at all.
Just over half of patients felt that doctors didn’t consider their ability to pay when prescribing a drug, while nearly half blamed drugmaker’s influence for physicians’ prescribing habits. (HealthLeaders Media)
*This blog post was originally published at ACP Internist*
August 25th, 2010 by Toni Brayer, M.D. in Better Health Network, Health Policy, News, Opinion, Research
No Comments »
The top moneymakers for the U.S. pharmaceutical industry might surprise you. These aren’t necessarily the most prescribed medications (although some of them are), but they’re the top products in terms of sales in 2009. The revenues were in billions:
1. Lipitor – used for high cholesterol: $7.5 billion
2. Nexium – a proton pump inhibitor for GERD: $6.3 billion
3. Plavix – a blood thinner: $5.6 billion
4. Advair Diskus – used for asthma and COPD: $4.7 billion Read more »
*This blog post was originally published at EverythingHealth*
August 19th, 2010 by Medgadget in Better Health Network, News, Research
No Comments »
The UK supermarket chain Sainsbury’s is running a trial with two different drug vending machines in two of its West Sussex stores. Basically you can drop your prescription at the machine, the pharmacy will collect the prescriptions and deliver the medications which you can later pick up.
As the machines are placed in stores with an in-store pharmacy service, the only benefit seems to be the lack of face-to-face contact (for those people who consider that a benefit). The trial will run for a year after which it will be decided whether they will be rolled out across all of England. Read more »
*This blog post was originally published at Medgadget*
